SYNOPSIS Two patients with Huntington's chorea are reported whose psychiatric and neurological symptoms greatly improved after treatment with L-dopa. In both cases the basal values of CSF HVA were markedly decreased, being increased by the treatment with L-dopa.
The so-called clinical opposition between Parkinson's disease and Huntington's chorea has its pharmacological and biochemical counterparts. Choreic movements are improved by a variety of agents that deplete the brain of monoamines or interfere with dopamine at the receptor sites (for references see Barbeau, 1973) .
On the contrary, treatment with L-dopa, regarded, as is well known, as a dopamine (DA) replacement therapy ('specific though probably predominantly symptomatic ', Bernheimer et al., 1973) , markedly increases the choreic movements of Huntington's disease and, when used in patients with Parkinsonism at high doses or for a prolonged period of time, may cause the appearance of a variety of abnormal movements (Barbeau, 1969; Cotzias et al., 1969; Klawans and Garvin, 1969; Barbeau et al., 1971) .
Recent determinations of dopamine catabolites in CSF showed normal or low-normal values of homovanillic acid (HVA) in Huntington's chorea and diminished levels of HVA in Parkinson's disease (Bernheimer et al., 1966; Hornykiewicz, 1966; Birkmayer, 1969; Klawans, 1971; Guilleminault et al., 1973; Loeb et al., in press) . After a probenecid test HVA levels were similar to controls (Aquilonius and Sjiostrom, 1971 ; Lal et al., 1973) or about half that of control subjects (Chase, 1973 (Bernheimer et al., 1973) .
These findings in Huntington's disease seem to have the following exceptions:
1. A substantial diminution of HVA concentration in the cerebrospinal fluid, suggesting a reduction in dopamine metabolism, has been reported (Curzon et al., 1972; Chase, 1973) , even if no apparent correlation between HVA decrease and the severity of motor abnormalities could be established.
2. A few cases, some with lower levels of CSF HVA, associated with a good responsiveness to treatment with L-dopa, have been described by some authors (Tan et al., 1972; Schenk and Leijnse-Ybema, 1974 ).
We present two additional cases of Huntington's chorea with reduction of the CSF content in HVA, both of which were improved by treatment with L-dopa.
METHODS
Two unrelated female patients (case 1 and 2) with Huntington's chorea and a positive family histoiy involving two successive generations were studied ( Figure) . The disease, which had begun six and five years previously, showed at the onset only psychiatric disturbances, consisting of a paranoid reaction (case 1; C.A.) and a catatonic-like picture (case 2; V.I.); when referred for neurological examination they showed severe mental deterioration (Table 1) and such marked and diffuse choreic movements that speaking, walking, and feeding were rendered almost impossible. The patients were kept untreated and on a constant diet for 15 days; lumbar punctures were performed at 9 a.m. with the patient on her side, after having been fasted and confined to bed during the preceding 12 hours; levels of HVA, 5-HIAA, and MHPG were determined fluorometrically, according to the methods of Korf et al. (1969 Korf et al. ( , 1971a (Klawans, 1970) or increase in DA turnover (Curzon et al., 1972; Bernheimer and Hornykiewicz, 1973; Chase, 1973) , which, in turn, is dependent on the state of striatal DA receptors (Hornykiewicz, 1971 ).
There are good reasons to support the theory that the unbalanced dopaminergic relationship between the caudate nucleus and the putamen (Hornykiewicz, 1973) and/or the excessive stimulation of a damaged striatum by a relatively normal nigrostriatal DA pathway (Mardsen, 1975) could be the cause of choreic movements.
Nevertheless, the fact that in our cases L-dopa proved to be effective in checking choreic movements cannot be accounted for by this theory and must simply be taken as evidence for the existence of a peculiar variety of the disease for which there is still no convincing pathophysiological explanation.
